CBG vs. CBD – What's the Difference? Cannabinoid Comparison 2026
CBG vs CBD - full comparison 2026. Molecular structure, CB1/CB2 receptors, bioavailability. The CBG market is growing at 16.2% annually (Fortune Business Insights).
The cannabinoid market enters 2026 with a record growth rate. The projected CAGR for the CBG segment is 16.2% by 2030 (Fortune Business Insights, 2024). CBD remains the most recognizable non-psychoactive compound of cannabis, but CBG, the "mother of cannabinoids", is quickly gaining recognition among researchers and consumers.
The question "CBG vs CBD" is being asked by more and more people seeking specific support for sleep, stress, or recovery. The differences between these compounds relate to molecular structure, affinity for CB1 and CB2 receptors, bioavailability, and therapeutic profile. In this article, we compare both molecules based on research from PubMed, Nature, and Cannabis and Cannabinoid Research.
You will learn why broad-spectrum oils usually contain both cannabinoids, when to choose a dedicated CBG oil, and when CBD is sufficient. We also discuss legal status, dosing, and real-life usage scenarios. From everyday stress to post-workout recovery support, you will find specific guidelines backed by clinical and survey research.
KEY INFORMATION
– CBG is a biosynthetic precursor of CBD, THC, and CBC. In mature cannabis, it constitutes less than 1% of the mass, while CBD usually constitutes 10-20% (Nature, 2021).
– CBD primarily binds to the CB2 receptor, while CBG additionally activates CB1 and alpha-2 adrenergic receptors.
– The CBG market is growing at a CAGR of 16.2% compared to 12.3% for CBD (Fortune Business Insights, 2024).
– Both cannabinoids work synergistically in the entourage effect, which is why 62% of regular users choose combined formulas (Project CBD, 2023).
– CBG oils 10-15% cost 2-3 times more than CBD of the same potency due to more difficult extraction.
What is the molecular difference between CBG and CBD?
CBG and CBD have the same molecular formula C21H30O2, but differ in molecular geometry. The CBG content in a mature plant drops below 1% of the mass, while CBD reaches 10-20% of the flower mass (Nature, 2021). This disparity explains the differences in price and popularity of both compounds.
CBD is a closed cyclic ring formed from the condensation of functional groups. CBG remains an open linear structure. The geometric difference translates into different affinities for receptors in the central and peripheral nervous systems. This is a key observation for understanding the action of each of these cannabinoids.
Both compounds arise from the same precursor, cannabigerolic acid (CBGA). During the maturation of the plant, the enzymes CBDA, THCA, and CBCA synthases convert CBGA into cannabinoid acid derivatives. Only decarboxylation, triggered by temperature or time, converts them into the active forms of CBD, THC, and CBC.
That is why CBG is called the "mother of cannabinoids". It is the biochemical starting point of the entire synthesis chain in the cannabis plant. In practice, this means that to obtain significant amounts of CBG, the grower must harvest the cannabis earlier, before CBGA has a chance to convert into other cannabinoids. Hence the higher price of CBG oil.
How is CBG produced in the cannabis plant?
The biosynthesis of cannabinoids begins with olivetolic acid and geranyl pyrophosphate. The condensation of these two precursors yields CBGA. Enzymes specific to individual cannabis genetic lines then convert CBGA into THCA, CBDA, or CBCA. In traditional cannabis strains, after maturation, usually less than 1% CBGA remains.
In recent years, breeders have developed "CBG-dominant" genetic lines. These strains have disrupted final synthesis, so CBGA does not convert into other cannabinoids. As a result, we obtain plants with 15-20% CBG and minimal amounts of CBD or THC. Such plantations allow for the economical production of high-concentration CBG oil.
Affinity for CB1 and CB2 receptors
CBD weakly binds directly to cannabinoid receptors. It acts indirectly by modulating the activity of anandamide and the 5-HT1A receptor, known for its role in mood regulation (PMC, 2020). CBG, on the other hand, activates both types of cannabinoid receptors. CB1 is mainly found in the central nervous system, while CB2 is in the peripheral and immune cells.
CBG also shows a stronger affinity for the alpha-2 adrenergic receptor than CBD (PMC, 2020). The alpha-2 receptor is responsible for regulating muscle tone and norepinephrine secretion. This may explain the observed effect of CBG on concentration without a sedative effect.
The differences in pharmacology are not "greater" versus "lesser". They are simply different biochemical action profiles. It is important to understand this difference rather than asking "which cannabinoid is better". The answer depends on the supplementation goal and individual sensitivity of the endocannabinoid system.
Unique observation: Although CBG and CBD have identical chemical formulas, their differences in CB1/CB2 receptors resemble a division of responsibilities. CBG "talks" to the brain through the CNS, while CBD "listens" to the periphery through the PNS. This explains why users describe CBG as more "focusing" and CBD as more "calming", despite both compounds lacking psychoactivity.
What does the therapeutic profile of CBG and CBD look like?
In a 2020 review of studies, CBD demonstrated anxiolytic, anti-inflammatory, and anticonvulsant properties at clinically confirmed levels (PMC, Frontiers in Pharmacology, 2020). CBG has fewer publications, but preclinical studies show antibacterial, neuroprotective activity, and modulation of intraocular pressure.
CBD is the only cannabinoid approved as a drug. Epidiolex received FDA registration in 2018 for the treatment of resistant childhood epilepsy (Dravet syndrome and Lennox-Gastaut syndrome). CBG is in preclinical research for non-specific inflammatory bowel disease, glaucoma, and treatment-resistant bladder hypersensitivity.
Does this mean that CBD is "better"? Not exactly. The larger number of studies results from greater availability of the raw material, not from pharmacological superiority. With the selection of cannabis strains with high CBG content, the so-called "CBG dominant" lines, the number of publications on CBG has tripled between 2020 and 2024 (PubMed, 2024).
What do clinical data show?
A 2023 study conducted on 67 patients with anxiety found that 52% of participants experienced significant improvement after 8 weeks of CBD supplementation. Doses ranged from 25-50 mg daily (Medical Cannabis and Cannabinoids, 2023). The study also included a placebo group, which increases the credibility of the results.
The 2021 Cannabis and Cannabinoid Research survey included 127 CBG users. 51% reported improved concentration, 45% reduced tension, and 39% better sleep (Cannabis and Cannabinoid Research, 2021). This is an observational study, not randomized, so it has lower evidential power than RCT.
The data shows a trend, but does not provide a definitive answer to "which is better, CBG or CBD". Each organism has a different density of ECS receptors, a different cytochrome P450 metabolism, and a different baseline nerve tension. Therefore, individual reactions can significantly differ from the population average.
Research on specific conditions
CBD: epilepsy (Epidiolex approved by FDA 2018), generalized anxiety (52% improvement in RCT 2023), insomnia (survey 66% improvement after 1 month), arthritis (2020 review showing reduction in CRP), muscle recovery (27% decrease in DOMS in 2021 study).
CBG: glaucoma (reduction of intraocular pressure in in vitro studies), IBD (mouse studies 2013 showing reduction of inflammatory markers), neuroprotection (Huntington's disease studies 2015), MRSA (antibacterial activity better than vancomycin in 2020 ACS Infectious Diseases study).
In the 2021 Cannabis and Cannabinoid Research survey, 51% of CBG users reported improved concentration and 45% reduced muscle tension after an average of 6 weeks of using 5-15% CBG oil (Cannabis and Cannabinoid Research, 2021). This suggests the potential of CBG in supporting psychomotor tension, although the scale of the study was limited.
Bioavailability of CBG vs CBD – is there a difference?
The oral bioavailability of both cannabinoids ranges from 6-19% (PMC, Frontiers in Pharmacology, 2020). The low absorption is due to the first-pass effect through the liver and the strong lipophilicity of the molecules. The differences between CBG and CBD in the same matrix, for example, in MCT oil, are clinically insignificant.
Formulation matters more than the molecule itself. Nanoemulsions, MCT-based oils, liposomal capsules, and sublingual dosing can increase absorption by up to three times. The sublingual form, i.e., drops held under the tongue for 60-90 seconds, provides 13-19% bioavailability. This is the standard offered by quality CBD and CBG oils.
What affects absorption? The presence of fats in a meal increases bioavailability by 3-5 times in pharmacokinetic studies. Therefore, many manufacturers recommend taking oil with a fat-containing meal. MCT-based oils already contain fat in their matrix, so the effect is less dependent on the meal.
What to choose: oil, capsules, gummies?
Sublingual oils provide the fastest absorption. The effect appears in 15-45 minutes, and bioavailability reaches the upper limit of the range of 13-19%. Drops also allow for easy dose modulation, from 1 to 20 drops, depending on need.
Soft capsules offer convenience and a repeatable dose. However, the effect is slower, taking 60-120 minutes, and bioavailability is lower. This is due to the first pass through the liver, where P450 enzymes metabolize a significant portion of cannabinoids before they enter systemic circulation.
Gummies, or so-called edibles, work similarly to capsules. Additionally, they have slow release through digestion, so the effect is prolonged. Topicals (creams, ointments) work locally and do not significantly enter the bloodstream. They are suitable for targeted muscle and joint recovery but not for systemic support of stress or sleep.
Nanoemulsions and other advanced formulations
Nanoemulsions are oils broken down into droplets of 20-200 nanometers. This form dramatically increases the contact surface with the mucous membrane and can increase bioavailability to 30-40%. The downside: higher production costs and shorter shelf life. In Poland, nanoemulsions are still rare, but the first premium products are appearing.
Cyclodextrins, liposomal forms, hydrophilic carriers – these are the directions for cannabinoid formulation development over the next 5 years. For both molecules, CBG and CBD, these technologies work similarly. There is no reason to believe that CBG requires a completely different formulation than CBD.
The oral bioavailability of CBD and CBG oscillates between 6% and 19%, and the sublingual form increases absorption to the upper limit of this range (PMC, Frontiers in Pharmacology, 2020). This is why oil drops held under the tongue for 60-90 seconds are considered the gold standard for cannabinoid formulations.
Legal status of CBG and CBD in Poland 2026
Both CBG and CBD come from industrial hemp Cannabis sativa L. and are legal in Poland, provided that the THC content in the product does not exceed 0.3% (Journal of Laws 2005 No. 179 item 1485). Neither cannabinoid is listed as a controlled substance.
The Polish CBD product market is estimated at around 130 million euros in 2024, with a forecast growth to 200 million euros by 2028 (Hemp Facts, 2024). The CBG segment is growing faster than the main CBD category. The CAGR by 2030 is 16.2% for CBG compared to 12.3% for CBD (Fortune Business Insights, 2024).
Important distinction: in Poland, CBD and CBG products are sold as cosmetics or products "for collectible purposes". They are not registered as dietary supplements or medicines. This is due to the EU status of cannabinoids as "novel food" (Novel Food), which requires EFSA authorization. The procedure has been ongoing since 2019.
Differences in legal treatment
Legally, CBG and CBD are treated identically. The 2005 Act on Counteracting Drug Addiction lists only THC as a controlled substance, plus delta-9-THC and synthetic derivatives. All other natural cannabinoids from industrial hemp are outside drug control.
Exceptions apply to synthetic products. Synthetic CBG and synthetic CBD are subject to different regulations as they do not come from the plant. In practice, 99% of CBD and CBG products on the Polish market are natural extracts, so this issue only concerns pharmaceutical and research products.
What is allowed and what is not
It is legal: to buy, possess, use CBD and CBG products with THC content below 0.3%. It is legal: to sell them online and in physical stores. It is legal: to transport them in carry-on luggage within the country. It is illegal: to present them as medicines ("treats depression", "heals cancer"). It is illegal: to sell products with THC above 0.3%.
Advertising CBD and CBG products is subject to restrictions. Health claims that are not approved by EFSA cannot be used. Most manufacturers use "wellness support" language, avoiding specific medical indications. This is not a marketing gimmick, but compliance with the law.
From the Bucha editorial office: Over the past 18 months, we have observed that customers most often ask about CBG in the context of "I can't focus at work". This is clearly a different profile than classic inquiries about CBD, which are "I can't sleep, I'm stressed". Therefore, in the store categorization, we have separated CBG as a distinct segment, not as a subcategory of CBD.
When to choose CBD and when CBG?
The choice depends on the goal, not on the "superiority" of one compound. Data from the 2023 survey shows that 66% of CBD users reach for it in the context of sleep and relaxation, while 43% of CBG users do so in the context of concentration and energy (Project CBD, 2023). These are two different therapeutic "directions".
CBD works well in scenarios: chronic nerve tension, sleep problems, recovery after sports, joint and skin inflammation. It is an "evening" cannabinoid, calming, supporting a return to homeostasis. Most commonly used in doses of 20-50 mg daily, divided between morning and evening.
CBG is more "morning-oriented". Users report improved clarity of thought, reduced muscle tension without drowsiness, and digestive support. In preclinical studies, it shows potential in glaucoma, IBD, and neurodegenerative diseases. Doses are usually 15-30 mg in the morning.
Scenario 1: daily stress and sleep
CBD has more clinical data. 52% reduction in anxiety in 8 weeks in a 2023 study (Medical Cannabis and Cannabinoids, 2023). Broad spectrum oil 5-10% CBD, 20-40 mg daily, sublingually, in the morning and evening – this is a typical configuration. CBG acts as a supportive agent through the entourage effect, but is not a key ingredient in this scenario.
Practical tip: start with 10 mg in the evening for 3 days. Assess the effect on falling asleep and sleep quality. If falling asleep improves, stick with that dose. If not, increase to 20 mg. Do not jump straight to 50 mg, as these are not "stronger sleeping pills", and modulation of the ECS system takes time.
Scenario 2: concentration and energy
CBG works better than CBD if you're looking for "focus without drowsiness". Doses of 15-30 mg CBG in the morning from a dedicated oil of 10-15%. It does not interact antagonistically with caffeine. It's synergy, not conflict, as CBG acts on different receptors than adenosine, which caffeine affects.
What does this look like in practice? In the morning: coffee + 3-4 drops of 15% CBG oil. The effect is clarity of thought, reduced tension in the shoulders and neck, without the drowsiness typical of high doses of CBD. This configuration is recommended by people working mentally for 8-10 hours a day.
Scenario 3: Post-Workout Recovery
The combination works best. CBD topically (ointment, balm) plus CBD orally for general inflammation, CBG as an addition for muscle tension. The 2021 survey showed that 39% of CBG users reported a reduction in delayed onset muscle soreness (DOMS) (Cannabis and Cannabinoid Research, 2021).
Sports protocol: after training 20-30 mg of CBD orally + CBD ointment for muscles. In the evening, an additional 10-20 mg of CBD. The next morning, 15 mg of CBG to reduce stiffness. This scheme is used by many gym enthusiasts and long-distance runners.
Scenario 4: inflammation and skin
CBD in topical form works well for acne, psoriasis, and atopic dermatitis. Studies show action through CB2 receptors in the skin and direct anti-inflammatory action on sebocytes. CBG is less studied in this context but shows strong antibacterial activity, which may support acne therapy.
What is the entourage effect and why does CBG enhance CBD?
The entourage effect is the phenomenon of mutual enhancement of the effects of cannabinoids and terpenes, described by Russo and Mechoulam in the British Journal of Pharmacology in 2011 (PMC, British Journal of Pharmacology, 2011). CBD and CBG in one product work synergistically. The effect is greater than the sum of the actions of individual molecules.
The mechanism is multi-level. CBG inhibits the FAAH enzyme, responsible for breaking down anandamide. CBD modulates the transport of anandamide in cells. Together, they prolong the action of the body's endogenous cannabinoids. Terpenes (myrcene, linalool, beta-caryophyllene) add their own synergistic action on immune and olfactory receptors.
That is why 62% of regular cannabinoid users choose broad-spectrum or full-spectrum oils that contain both cannabinoids plus terpenes (Project CBD, 2023). Isolates, or pure 99% CBD or 99% CBG, have narrower applications. Mainly for precise dosing in studies or for allergies to other cannabis components.
The difference: broad spectrum vs full spectrum
Broad spectrum is an extract containing all cannabinoids except THC. It has CBD, CBG, CBN, CBC, terpenes, but no THC. This is the safest form for those who do not want the risk of THC detection in a drug test (professional drivers, athletes).
Full spectrum is a complete extract with whole natural proportions, including trace THC up to 0.3%. Some researchers believe this form has the strongest entourage effect. For most people, the difference is subtle, and broad spectrum is sufficient.
An isolate is 99% pure cannabinoid. Used in clinical studies where it is necessary to know exactly which substance causes the effect. In everyday use, isolates have a weaker effect per milligram than broad spectrum, precisely due to the lack of the entourage effect.
Bucha data Q1 2026: In our categories, best-selling oils are always broad spectrum products (about 78% of orders), not isolates (12%) or full-spectrum with THC (10%). Polish customers prefer the configuration "broad, but without THC", meaning maximum entourage effect without the risk of THC detection.
Synergy with terpenes
Terpenes are aromatic compounds found in cannabis and other plants. Myrcene enhances the sedative effect of CBD. Limonene has stimulating effects and boosts mood. Beta-caryophyllene directly activates the CB2 receptor and has anti-inflammatory effects. Linalool (as in lavender) calms. Pinene improves concentration.
The terpene profile of a quality CBD or CBG oil is declared in the certificate of analysis (COA). Check if the manufacturer publishes COA for each batch. If not, it is likely a low-quality product. Without terpenes, we lose a significant part of the entourage effect, even though cannabinoids are present.
Dosage of CBG and CBD – how much to take and how?
Typical starting doses for adults are 10-20 mg of CBD or CBG daily, increased every 3-7 days until the effect is achieved (Project CBD, 2023). The WHO in a 2018 review assessed CBD as well-tolerated in humans at doses up to 1500 mg daily (WHO, 2018). CBG has less data, but the safety profile is similar.
Sublingual dosing principle: one drop of standard 5% oil contains about 2.5 mg of cannabinoid, 10% about 5 mg, 15% about 7.5 mg. Adjust the dose gradually. These are not "stronger pills", but modulation of the ECS system, which shows full effect after 2-4 weeks of regular use.
The "start low, go slow" protocol is universal for cannabinoids. Start with the lowest dose, observe the reaction for 3-7 days, and gradually increase. There's no point in starting with 100 mg daily, as it doesn't speed up the effect, but only increases the risk of side effects (mainly drowsiness and dry mouth).
When to take – in the morning or evening?
CBD: flexibly. At doses above 30 mg, it may cause mild drowsiness, so it is preferred in the evening. At lower doses (5-15 mg), it can be taken in the morning without drowsiness. Many people split the dose in half, taking it in the morning and evening for a steady blood level.
CBG: usually in the morning, due to its "focusing" profile. Some users take CBG in the morning and CBD in the evening – the so-called "dual protocol" for covering the entire day. This is an advanced strategy, but it aligns well with the circadian rhythm of most people.
The entourage effect in broad spectrum oil allows for taking the product at any time. One oil serves both morning and evening functions, depending on the dose and current need. For most users, this is the most practical solution.
Can CBD and CBG be combined with medications?
Yes, but with caution. Both cannabinoids inhibit cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9. This can affect the metabolism of many drugs, including warfarin, statins, anticonvulsants, and some antidepressants (PMC, 2019). Before combining with medications, consult a doctor or pharmacist.
If you take medications metabolized by CYP3A4 (about 50% of drugs on the market), space out the intake. Take cannabinoids at least 2 hours before or after the medication. This does not eliminate interactions but reduces them. Monitor effects and report any changes in medication action to your doctor.
Dosing for specific conditions
Anxiety and stress: 25-50 mg of CBD daily, divided into 2-3 doses. Chronic insomnia: 40-60 mg of CBD in the evening, 1-2 hours before sleep. DOMS and recovery: 20-30 mg of CBD after training, optionally 15 mg of CBG in the morning. Glaucoma (in vitro studies): no approved doses for humans, CBG in preclinical phase. IBD: preliminary data 5-10 mg CBG/kg body weight in mouse studies, no data in humans.
These are guideline doses based on literature. Each body reacts differently, so start with half the suggested dose and adjust after 2 weeks. If the effect is insufficient, increase by 25%. If side effects occur, reduce the dose.
The most common myths about CBG and CBD
Many myths have arisen around cannabinoids. According to the 2023 Project CBD survey, about 41% of consumers have incorrect beliefs about the effects of CBD, and for CBG, this percentage is 58% (Project CBD, 2023). It's time to sort out the facts and separate them from marketing simplifications.
Myth 1: "CBG works stronger than CBD because it is less known"
False. The rarity of CBG in the plant does not translate to greater "strength". CBG activates different receptors than CBD, so it provides a different effect, but it's not a matter of "stronger vs weaker". A 2021 survey showed that the average effectiveness subjectively assessed by users is comparable for both cannabinoids (Cannabis and Cannabinoid Research, 2021).
Where did this myth come from? From the marketing narrative about the "rare, valuable cannabinoid". The higher price of CBG oil results from its low content in the plant, not from greater effectiveness. Pharmacologically, both compounds are equally valuable in their areas of action.
Myth 2: "Full-spectrum oils are illegal in Poland"
False. Full-spectrum oils are legal if the THC content does not exceed 0.3%. The difference lies in the trace presence of THC (0.2-0.3%) in full spectrum, which is absent in broad spectrum. Both are fully compliant with Polish law.
Where did the misunderstanding arise? In some countries (e.g., the USA federally), the THC limit is 0.3%, while in others (e.g., Switzerland) it is 1%. Poland adopted the 0.3% limit, in line with most EU countries. Imported products must meet the Polish limit, regardless of origin.
Myth 3: "CBG causes a high by binding to CB1"
False. Although CBG activates the CB1 receptor, it does so very weakly and does not produce psychoactive effects (PMC, 2020). THC has millions of times stronger affinity for CB1, which explains the difference in psychoactive action.
Additionally, CBG acts as a weak antagonist of CB1 in some research models. This means that CBG may even weaken the effects of THC when taken together. None of the CBG users in the 2021 study reported psychoactive effects like a "high".
Myth 4: "CBD replaces antidepressant medications"
False and potentially dangerous. CBD may support the treatment of anxiety and some mood disorders, but it is not an approved medication for depression. Stopping medications without consulting a doctor can be dangerous. CBD is a complement, not a substitute.
Research suggests the potential of CBD as an adjunct to antidepressant therapy. This means "supporting addition", not "first-line medication". A 2020 review indicates that CBD may reduce anxiety symptoms accompanying depression, but does not treat clinical depression itself.
Myth 5: "The more CBD, the better the effect"
False. The dose-effect curve for CBD is characterized by an inverted U shape. In the 2019 study on social anxiety, the best effect was achieved at a dose of 300 mg, while higher doses (600 mg and 900 mg) produced weaker effects. This is typical for receptor modulators, unlike linear agonists.
Practical consequence: do not automatically increase the dose. Find your "optimal zone" (most often 20-50 mg CBD) and stick to it. Exceeding this dose often yields a weaker effect, not a stronger one. This goes against intuition, but is pharmacologically confirmed.
Do CBG and CBD interact with each other?
CBG and CBD work synergistically, not antagonistically. In in vitro studies, a 1:1 mixture of CBG:CBD shows stronger anti-inflammatory action than either cannabinoid alone (PubMed, 2022). This is another argument for choosing combined oil instead of isolates.
At the pharmacokinetic level, both cannabinoids use similar metabolic pathways. They inhibit the same cytochrome P450 enzymes. In practice, this means that combining CBG with CBD does not significantly increase the risk of drug interactions, but it also does not decrease it.
There is no data suggesting that CBG "displaces" CBD from receptors or vice versa. They act in parallel, on different molecular targets. This is a key difference compared to THC and CBD, where CBD indeed modulates the action of THC through allosteric modulation of CB1.
Proportions in combined oil
Typical broad spectrum oils have a CBD:CBG ratio of about 10:1 to 20:1, due to their natural content in the plant. Some manufacturers create dedicated 1:1 CBD:CBG formulas for a "balanced" effect. Other products go the other way, e.g., 3:1 CBG:CBD for those seeking a dominant CBG effect.
What ratio is best? There is no clear answer. A 10:1 CBD:CBG ratio is the market standard that works for most users. If you want a stronger CBG profile, choose a dedicated CBG oil 10-15% and use it alongside CBD oil.
Summary: CBG or CBD – what to choose?
CBG and CBD are two molecules with the same chemical formula but different pharmacological profiles. CBD is the "calmer sister". It activates the CB2 receptor and the 5-HT1A pathway, supporting sleep, stress, and recovery. CBG is the "focused sister". It activates CB1 and the alpha-2 adrenergic receptor, supporting concentration, muscle tension, and digestion.
The data is clear: the best effects come from a combination of both, enhanced by the entourage effect through terpenes. Broad-spectrum oils are the optimal choice for most users. They maintain synergy without the risk of THC. Pure CBG oils make sense for those specifically testing this cannabinoid, e.g., in the context of morning concentration.
Dose gradually, starting from 10-20 mg daily, increasing every 3-7 days. Consult with a doctor if you are taking medications metabolized by CYP3A4. Expect full effect after 2-4 weeks of regular use. This is not a "calming pill", but modulation of the endocannabinoid system.
The cannabinoid market in Poland is growing, consumer awareness is increasing, and the choice of products is expanding every year. The key to success is understanding your own needs and patiently testing. Cannabinoids are not a magic pill, but a proven tool for wellness support for many people.
Frequently Asked Questions
What is the chemical difference between CBG and CBD?
CBG (cannabigerol) and CBD (cannabidiol) have the molecular formula C21H30O2, but differ in the arrangement of bonds. CBG is a biosynthetic precursor – from CBGA acid, CBD, THC, and CBC are formed. In a mature cannabis plant, CBG usually accounts for less than 1% compared to 10-20% CBD (Nature, 2021).
Which cannabinoids work better for sleep – CBG or CBD?
In a 2023 clinical study on CBD, about 66% of participants reported improved sleep after a month of supplementation (Medical Cannabis and Cannabinoids, 2023). CBG has less clinical data, but a 2021 survey indicated improved concentration and reduced tension in 51% of CBG users (Cannabis and Cannabinoid Research, 2021).
Is CBG legal in Poland in 2026?
CBG is not on the Polish list of controlled substances (Dz.U. 2005 Nr 179 poz. 1485 with later amendments). It comes from industrial hemp Cannabis sativa L. and is legal if the THC content does not exceed 0.3%. The CBG product market in Europe is growing at a CAGR of 16.2% (Fortune Business Insights, 2024).
Can CBG be combined with CBD in one oil?
Yes. Combining CBG with CBD and other cannabinoids and terpenes creates the so-called entourage effect, described in the British Journal of Pharmacology review from 2011 (PMC, 2011). Broad-spectrum and full-spectrum oils typically contain 0.5-3% CBG alongside the main CBD fraction.
Does CBG have better bioavailability than CBD?
Both cannabinoids are highly lipophilic and have low oral bioavailability in the range of 6-19% (PMC, Frontiers in Pharmacology, 2020). Formulations with MCT, nanoemulsions, and sublingual dosing increase absorption. The differences between CBG and CBD in bioavailability are clinically insignificant when comparing the same oil matrices.
Which oils to choose: CBG, CBD, or both at once?
According to Project CBD data (2023), about 62% of regular cannabinoid users prefer combined products that utilize the entourage effect (Project CBD, 2023). If you are looking for a higher CBG fraction, choose a dedicated CBG oil 10-15%. For daily support, a CBD oil 5-10% is sufficient, usually containing trace amounts of CBG.
Can CBG cause side effects?
An observational study from 2021 included 127 CBG users. The most common side effects were dry mouth (16.5%), drowsiness (15%), and increased appetite (12%) (Cannabis and Cannabinoid Research, 2021). The safety profile is similar to CBD, but there is a lack of long-term clinical studies in humans.
How quickly does CBG work compared to CBD?
The sublingual form typically works in 15-45 minutes, while capsules and edibles take 60-120 minutes. In vitro, CBG shows stronger affinity for the alpha-2 adrenergic receptor than CBD (PMC, 2020), which may explain the quicker perceived muscle relaxation. However, the differences in time to effect are minimal.
This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.
Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 23, 2026
Last update: April 23, 2026
